Psilocybin Treatment of Tobacco Addiction

As part of the ongoing Student/Postdoc-Run Speaker Series (SPRSS), and on behalf of the Neural Mechanisms of Psychedelic Drug Action Group, Dr. Matthew Johnson from Johns Hopkins Medicine will give a talk titled "Psilocybin Treatment of Tobacco Addiction." The talk can also be accessed via Zoom here.

Abstract: Annual tobacco smoking-related deaths are estimated at 480,000 in the US and 5 million worldwide, dwarfing mortality for all other drugs of abuse. Most behavioral interventions and pharmacotherapies for smoking cessation result in only modest long-term success rates. A small pilot study published in 2014 found that among 15 treatment-resistant smokers, a program combining psilocybin with cognitive behavioral therapy resulted in very high success rates (e.g., 7-day point prevalence abstinence rates of 80% at 6-months after the target-quit-date).

View the Neural Mechanisms of Psychedelic Drug Action Group program here.